KR20030097611A - 골 흡수 억제를 위한 조성물 - Google Patents

골 흡수 억제를 위한 조성물 Download PDF

Info

Publication number
KR20030097611A
KR20030097611A KR1020027013595A KR20027013595A KR20030097611A KR 20030097611 A KR20030097611 A KR 20030097611A KR 1020027013595 A KR1020027013595 A KR 1020027013595A KR 20027013595 A KR20027013595 A KR 20027013595A KR 20030097611 A KR20030097611 A KR 20030097611A
Authority
KR
South Korea
Prior art keywords
once
bisphosphonate
group
histamine
twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027013595A
Other languages
English (en)
Korean (ko)
Inventor
다이포티스아나스타시아지
산토라아더씨2세
야테스에이존
Original Assignee
머크 앤드 캄파니 인코포레이티드
한국 엠에스디 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20030097611(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by 머크 앤드 캄파니 인코포레이티드, 한국 엠에스디 주식회사 filed Critical 머크 앤드 캄파니 인코포레이티드
Publication of KR20030097611A publication Critical patent/KR20030097611A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
KR1020027013595A 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물 Ceased KR20030097611A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US60/053,351 1997-07-22
US5353597P 1997-07-23 1997-07-23
US60/053,535 1997-07-23
GB9717590.5 1997-08-20
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption
GB9717850.3 1997-08-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020007000680A Division KR100391732B1 (ko) 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물

Publications (1)

Publication Number Publication Date
KR20030097611A true KR20030097611A (ko) 2003-12-31

Family

ID=27451690

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020027013595A Ceased KR20030097611A (ko) 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물
KR1020007000680A Expired - Fee Related KR100391732B1 (ko) 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물
KR1020027013594A Ceased KR20030097610A (ko) 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020007000680A Expired - Fee Related KR100391732B1 (ko) 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물
KR1020027013594A Ceased KR20030097610A (ko) 1997-07-22 1998-07-17 골 흡수 억제를 위한 조성물

Country Status (31)

Country Link
EP (5) EP0998292B1 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097611A (enExample)
CN (3) CN1602879A (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE122006000009I1 (enExample)
DK (2) DK1175904T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT1175904E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916326T2 (de) * 1998-12-25 2005-03-17 Yamanouchi Pharmaceutical Co., Ltd. Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
NZ515541A (en) * 1999-05-21 2003-03-28 Novartis Ag Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
CN100349574C (zh) * 1999-07-19 2007-11-21 东丽株式会社 牙周疾病用剂
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
DE60113537T3 (de) 2000-06-20 2013-05-29 Novartis Ag Methode zur verabreichung von biphosphonaten
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
DE60317061T2 (de) * 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag Ibandronsäure zur behandlung und vorbeugung von osteoporose
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
EP1937362B1 (en) * 2005-09-16 2013-03-27 Selamine Ltd. Bisphosphonate formulation
KR20170104664A (ko) * 2010-12-06 2017-09-15 에프락스 파머슈티컬즈 소시에떼 아노님 신속한 용해 특성을 구비한 안정한 발포성 비스포스포네이트 제형
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ES2074769T3 (es) * 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
ATE256456T1 (de) * 1996-05-17 2004-01-15 Merck & Co Inc Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
CA2294595C (en) 2001-08-21
IS5315A (is) 1999-12-21
NO20000323L (no) 2000-03-20
EP1175904A2 (en) 2002-01-30
CY2007022I2 (el) 2012-01-25
KR20010022110A (ko) 2001-03-15
ATE357921T1 (de) 2007-04-15
UY25950A1 (es) 2000-09-29
JP2005068010A (ja) 2005-03-17
EP1175903A2 (en) 2002-01-30
CY1107535T1 (el) 2012-01-25
EA004544B2 (ru) 2006-12-29
CN1265035A (zh) 2000-08-30
KR20030097610A (ko) 2003-12-31
BR9810779A (pt) 2000-07-25
DE01201911T1 (de) 2007-10-18
DE69803291T2 (de) 2002-08-08
LU91222I2 (fr) 2006-04-18
CY2007022I1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
NL300292I1 (nl) 2007-11-01
EA200000151A1 (ru) 2000-10-30
PL338635A1 (en) 2000-11-06
EP1132088A3 (en) 2002-04-24
CN1166365C (zh) 2004-09-15
SI0998292T1 (en) 2002-04-30
HK1040494A1 (en) 2002-06-14
LU91364I2 (fr) 2007-11-12
WO1999004773A9 (en) 1999-10-28
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
BG66282B1 (bg) 2013-01-31
CN1299689C (zh) 2007-02-14
HK1040495A1 (en) 2002-06-14
EE200000040A (et) 2000-10-16
DE01201913T1 (de) 2007-02-08
DE122006000009I1 (de) 2006-06-14
BG104093A (en) 2000-10-31
EP1151752A3 (en) 2002-12-18
EP1175904B1 (en) 2007-03-28
EP1132088A2 (en) 2001-09-12
HK1024166A1 (en) 2000-10-05
EE05603B1 (et) 2012-12-17
DE69803291D1 (de) 2002-02-21
TR200000145T2 (tr) 2000-05-22
SG109478A1 (en) 2005-03-30
ES2269014T3 (es) 2007-05-01
DK1175904T3 (da) 2007-05-07
PT998292E (pt) 2002-04-29
KR100391732B1 (ko) 2003-07-16
CA2294595A1 (en) 1999-02-04
CN1602880A (zh) 2005-04-06
HK1042232A1 (en) 2002-08-09
EP0998292A2 (en) 2000-05-10
EA004544B1 (ru) 2004-06-24
CN1602879A (zh) 2005-04-06
ES2269014T1 (es) 2007-04-01
NL300223I1 (nl) 2006-04-03
IS7231A (is) 2004-04-21
EP1175904B8 (en) 2007-05-09
IL133535A0 (en) 2001-04-30
EP1151752A2 (en) 2001-11-07
EP1175904A3 (en) 2002-12-18
NZ501807A (en) 2003-02-28
DE69837450D1 (de) 2007-05-10
EP1175903A3 (en) 2002-12-18
JP3479780B2 (ja) 2003-12-15
IS7230A (is) 2004-04-21
AU8493698A (en) 1999-02-16
PL195272B1 (pl) 2007-08-31
ES2253136T1 (es) 2006-06-01
HK1042230A1 (en) 2002-08-09
EP0998292B1 (en) 2001-11-21
ES2164447T3 (es) 2002-02-16
PT1175904E (pt) 2007-04-30
JP2002502433A (ja) 2002-01-22
ID24096A (id) 2000-07-06
DE69837450T2 (de) 2007-08-23
WO1999004773A3 (en) 1999-04-15
SK932000A3 (en) 2000-09-12
ATE209037T1 (de) 2001-12-15
DK0998292T3 (da) 2002-05-13
DE122007000063I1 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
US6333316B1 (en) Method for inhibiting bone resorption
US6015801A (en) Method for inhibiting bone resorption
US6465443B2 (en) Method for inhibiting bone resorption
KR100391732B1 (ko) 골 흡수 억제를 위한 조성물
GB2336311A (en) Bisphosphonate Dosing Regimen
IL153109A (en) An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture
MXPA00000789A (en) Method for inhibiting bone resorption
CA2349733A1 (en) Inhibition bone resorption
AU1567702A (en) Method for inhibiting bone resorption

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20021010

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021014

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030721

Patent event code: PE09021S01D

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050321

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050725

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050321

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20030721

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I